Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific share transactions.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.400 per share.
- Transaction Volume: 24 shares (Mr. D S Redfern) and 20 shares (Mrs. V A Whyte).
- Transaction Date: January 11, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by executives following the re-investment of dividends paid on January 10, 2019, within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Verify the dividend payment date of January 10, 2019, to confirm the timing of the reinvestment.
- Confirm the share price of £15.400 on the London Stock Exchange for January 11, 2019.
- Note that the transactions were executed within ISAs, which may have specific tax implications for the executives.
- Identify the PDMRs involved: Mr. D S Redfern (Chief Strategy Officer) and Mrs. V A Whyte (Company Secretary).